Our findings suggest that sIL-2R could possibly be employed to assess the biological behavior and progression of ccRCC, as well as to predict the response to IFN-alpha combined with sequential VEGF-targeting therapy. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.